NCT06358053尚未招募1 期
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cells in HLA-A*02:01+ Subjects With HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers and Other Solid Tumors
Corregene Biotechnology Co., Ltd0 个研究点目标入组 24 人开始时间: 2024年4月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
- 主要终点
- cevents (SAEs).
研究概览
简要总结
A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years and 65 years.
- •Patients with advanced solid tumors (such as cervical cancer, head and neck tumors, anal cancer, and other malignancies) who have failed standard treatment confirmed by histology and/or cytology, or who are intolerant to such treatment, and for whom there is no effective therapy available after standard treatment failure are considered as end-stage patients. Specifically for:
- •Cervical cancer: a) Patients who have previously failed at least second-line systemic therapy (including at least one platinum-based regimen or anti-angiogenic therapy) and have shown disease progression or intolerance confirmed by pathological or radiological examination during or after the most recent treatment course, and are not amenable to treatment with surgery or radiotherapy, with no standard treatment options currently available for recurrent or metastatic cervical cancer.
- •Nasopharyngeal cancer: a) Patients who have previously failed at least third-line systemic therapy or are intolerant, not amenable to treatment with surgery or radiotherapy, with no standard treatment options currently available for recurrent or metastatic nasopharyngeal cancer; b) EB virus negative.
- •Head and neck squamous cell carcinoma: a) Patients who have previously failed at least second-line systemic therapy or are intolerant, with no standard treatment options currently available for recurrent or metastatic head and neck squamous cell carcinoma (non-nasal).
- •Confirmation of HPV16 positive and HLA-A*02:01 allele.
- •ECOG performance status of 0-
- •Estimated life expectancy ≥ 3 months.
- •Patients must have at least one measurable lesion defined by RECIST 1.
- •Female patients of childbearing age must undergo a serum pregnancy test within 7 days prior to study treatment and the results must be negative, and are willing to use a very effective and reliable method of contraception from screening through 6 months after the last dose of study treatment.
- •The patient must be willing to sign the informed consent form and have a good anticipation of compliance with study procedure.
排除标准
- •Patient received any genetically modified T cell therapy.
- •Patient is being treated with T cell immunosuppressive agent （such as cyclophosphamide, FK506,tripterygium glycosides） or T cell immunoagonist.
- •Patients received chemotherapy, targeted therapy, immunotherapy, or other investigational agents within 2 weeks and received radiotherapy within 4 weeks before apheresis.
- •Patients have any organ system function impairment as defined below:
- •leukocytes<3.0 x 109/L
- •absolute neutrophil count >1.5 x 109/L
- •hemoglobin<90g/L
- •platelets <100 x 1010/L
- •lymphocytes<0.5 x 109/L
- •percentage of lymphocytes<15%
- •creatinine>1.5×ULN or creatinine clearance <50mL/min
- •total bilirubin>3×ULN; ALT/AST>3×ULN (patients with liver metastasis,>5×ULN)
- •INR>1.5×ULN; APTT>1.5×ULN
- •Patinets has serious medical conditions, disorders, and / or comorbidities, including, but are not limited to: severe heart disease, cerebrovascular disease, epileptic seizures, uncontrolled diabetes (CTCAE 5.0: FBG ≥ 2 grade), active infection, active digestive tract Ulcer, gastrointestinal bleeding, intestinal obstruction, pulmonary fibrosis, renal failure, respiratory failure.
- •Patient has a severe cardiovascular disease with 6 months before screening, including, but are not limited to, myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Heart failure NYHA grade Ⅲ or Ⅳ.
- •Left Ventricular Ejection Fractions (LVEF) <50%.
- •Patient has a known active brain metastases.
- •Patient has a known myelodysplastic syndrome (MDS) or lymphoma.
- •Patient has a known active autoimmune disease, including , but are not limited to, acquired or congenital immunodeficiency disease, allogeneic organ transplantation, autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease.
- •Patient has a known active Hepatitis B or Hepatitis C.
- •Patient has a history of Human Immunodeficiency Virus (HIV) .
- •Patient has a history of syphilis.
- •Pregnant or lactating women.
- •Patient has a known active mental and neurological diseases.
- •The principal investigator judged that it is not suitable to participate in this clinical study.
研究组 & 干预措施
CRTE7A2-01 TCR-T cell therapy
Experimental
This study is a single-arm Phase I study, encompassing both dose escalation and dose expansion phases. Patients will undergo lymphocytapheresis, then treatment with TCR-T cell (at escalating doses) + IL-2
干预措施: CRTE7A2-01 TCR-T cell therapy (Drug)
结局指标
主要结局
cevents (SAEs).
时间窗: 2 years
Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).
RP2D
时间窗: 2 years
Recommended Phase 2 Dose
DLT
时间窗: 28 days
Dose-limiting toxicity
次要结局
- Progression-Free Survival (PFS)(2 years)
- Overall Survival(OS)(2 years)
- Objective Response Rate (ORR)(2 years)
- Disease Control Rate (DCR)(2 years)
- Duration of Response (DOR)(2 years)
研究者
相似试验
招募中
1 期
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck CancersHead and Neck CancersCervical CancerAnal CancerNCT05122221Corregene Biotechnology Co., Ltd12
招募中
1 期
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid TumorHead and Neck Squamous Cell CarcinomaVagina TumorCarcinoma of PenisAnal CarcinomaCarcinoma of VulvaCervical CancerOropharyngeal CancerNCT05787535HRYZ Biotech Co.17
招募中
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668Advanced Solid TumorNCT05341570Betta Pharmaceuticals Co., Ltd.60
招募中
1 期
A Study of BPI-460372 in Advanced Solid Tumor PatientsAdvanced Solid TumorNCT05789602Betta Pharmaceuticals Co., Ltd.82
进行中（未招募）
1 期
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid NeoplasmsRelapsed or Refractory Mature Lymphoid NeoplasmsNCT03603951Jiangsu HengRui Medicine Co., Ltd.272